Emerging Antimicrobials and Diagnostics 2023 is powered by our esteemed partners:
Innovate UK is the UK’s national innovation agency. We support business-led innovation in all sectors, technologies and UK regions. We help businesses grow through the development and commercialisation of new products, processes, and services, supported by an outstanding innovation ecosystem that is agile, inclusive, and easy to navigate.
Addressing the human health impacts of AMR will require building a strong and motivated coalition of like-minded health officials, clinicians, laboratorians, policymakers, patients and leaders.
LifeArc is a self-funded, charitable medical research organisation committed to spending £1.3 billion by 2030 in areas of high unmet medical need. Their teams are experts in drug and diagnostics discovery, technology transfer, and intellectual property and their work focuses on translational science – bridging the gap between academic research and clinical development. They provide funding, research and expert knowledge, all with a clear and unwavering commitment to having a positive impact on patient lives. They have been doing this for more than 25 years and their work has contributed to five licensed medicines, including cancer drug pembrolizumab (Keytruda®), and a diagnostic for antibiotic resistance.
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
BBC is a joint initiative of Department of Biotechnology, Government of India and Department of Electronics, IT, BT and S&T, Government of Karnataka. BBC is a State-of-the-art translational research and entrepreneurship centre catering to all the needs of start-ups in life science.
IHMA supports companies needing:
- Pre-clinical studies for regulatory filings
- Global laboratory services for all phases of clinical trials
- Antimicrobial resistance (AMR) surveillance (bacterial and fungal)
- Molecular characterization and detection of infectious agents
- New therapeutic approaches (bacteriophage, vaccine, etc.)
- In vitro diagnostic device studies
Molzym is committed to the development of innovative solutions to serve biological research and diagnosis of infectious diseases. Its developmental efforts are focused on new processes enabling and facilitating the molecular diagnosis of infectious diseases caused by bacteria and fungi.
NYtor is a knowledge-driven and reliable developer of innovative molecular diagnostic assays. Our company employs an enthusiastic and motivated team of highly skilled professionals with decades of expert experience and state-of-the-art knowledge of molecular diagnostic assay development. Tailor-made applications and approaches are an important aspect of our services, with a focus on long-term relationships based on personal interactions. We commit ourselves to molding your request into the most appropriate MDx system and technology any which way possible. Think of techniques like real time PCR, isothermal amplification (e.g. LAMP), digital PCR (dPCR) and systems like thermal cyclers, handheld devices for point-of-care (POC), and nanoscaled lab-on-a-chip (LOC).